Core Insights - Natera reported a revenue of $665.5 million for the quarter ended December 2025, reflecting a year-over-year increase of 39.8% [1] - The company's EPS was $0.35, a significant improvement from -$0.41 in the same quarter last year, indicating a positive turnaround [1] - The reported revenue exceeded the Zacks Consensus Estimate of $660.45 million by 0.76%, while the EPS surpassed the consensus estimate of -$0.46 by 175.43% [1] Financial Performance Metrics - The number of tests processed was 923,600, exceeding the average estimate of 903,207 from three analysts [4] - Licensing and other revenues reached $4.34 million, surpassing the estimated $2.32 million by four analysts, marking a 37.7% increase compared to the previous year [4] - Product revenues amounted to $661.16 million, exceeding the average estimate of $570.94 million from four analysts, also reflecting a 39.8% increase year-over-year [4] Stock Performance - Natera's shares have declined by 10.2% over the past month, contrasting with a 0.6% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3]

Core Insights - Guardant Health reported a revenue of $232.09 million for the quarter ended June 2025, reflecting a 31% increase year-over-year and surpassing the Zacks Consensus Estimate of $211.43 million by 9.77% [1] - The company’s EPS was -$0.44, an improvement from -$0.48 in the same quarter last year, with an EPS surprise of 15.38% against the consensus estimate of -$0.52 [1] Revenue Breakdown - Oncology revenue reached $158.69 million, exceeding the three-analyst average estimate of $153.38 million [4] - Licensing and other revenue was $2.57 million, surpassing the average estimate of $1.81 million from three analysts [4] - Screening revenue amounted to $14.81 million, significantly higher than the three-analyst average estimate of $8.31 million [4] - Biopharma and data revenue totaled $56.02 million, exceeding the average estimate of $48.06 million from three analysts [4] Stock Performance - Over the past month, shares of Guardant Health have declined by 14.6%, while the Zacks S&P 500 composite increased by 3.4% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]